Project Grant HT94252410662
Award Date
8/1/24
Completion Date
7/31/28
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Plandome, NY 11030, USA
Similar Awards
This federal Project Grant award, valued at $999,972.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports research by The Feinstein Institutes for Medical Research to study urine macrophages in lupus nephritis in order to shed light on kidney disease processes. This 4-year research project, with a period of performance from July 1, 2025 to June 30, 2029, aims to advance the understanding of...
The Feinstein Institutes for Medical Research was awarded a $655,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research characterizing immunological and genomic resistance mechanisms to anti-PD-1 immunotherapy in smoking-associated head and neck cancer. The grant period runs from April 15, 2022 to April 14, 2025. Through this funding, the Feinstein Institutes will investigate...
This federal Project Grant award of $708,000.00 provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The research project is focused on investigating the "Prevalence and Biologic Impact of FGFR3 Genomic Alterations in Bladder Cancer". The 2-year award period runs from September 15, 2023 to...
The Defense Health Agency awarded a $416,115 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Research Institute Of The Mcgill University Health Centre. The grant, awarded on August 15, 2024, will fund the development of next-generation prognostic tools for localized clear cell renal cell carcinoma through the integration of genomic, clinical, and pathological features. The award has a performance period ending on August 14, 2026. The Research...
The Defense Health Agency awarded a $464,261 project grant to The Royal Institution For The Advancement Of Learning, a private, non-profit educational institution in Montreal, Canada, to develop the next generation of prognostic tools for localized clear cell renal cell carcinoma. The grant, awarded under the Military Medical Research and Development (CFDA 12.420) program, will fund research to integrate genomic, clinical, and pathological features to create advanced prognostic tools for this...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,194,586 project grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The grant, awarded on September 30, 2023, will support a 3-year research project titled "COEVOLUTION OF METABOLISM AND IMMUNE MICROENVIRONMENT AS A DRIVER OF THERAPEUTIC RESPONSE AND METASTASIS IN CCRCC". Through this grant, the Sloan-Kettering Institute...
This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
The federal Project Grant award, valued at $2,685,519.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research at Cedars-Sinai Medical Center in West Hollywood, California to define human correlates of super-evasive disseminated tumor cells, assess their pathological relevance, and develop methods to eradicate them. The research project, which runs from July 1, 2025 to June 30, 2029, aims to transform...
This federal Project Grant award, valued at $178,999.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding research at Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to investigate targeting TFE3 fusion proteins using proteolysis-targeting chimera (PROTAC) in translocation renal cell carcinoma (TRCC). The research aims to develop innovative diagnostic and...